Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Cluster headache is pain that occurs along one side of the head. It frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing, and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.
The Cluster Headache Syndrome (Cluster Headache) Drugs in Development market research report provides an overview of the Cluster Headache Syndrome (Cluster Headache) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Cluster Headache), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects.
Cluster Headache Pipeline Drugs Market Targets
The targets of the cluster headache pipeline drugs market are 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 1D, Calcitonin Gene Related Peptide, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide Type 1 Receptor, 5-Hydroxytryptamine Receptor 2C, Calcium Channel, Cannabinoid Receptor 1, and Cannabinoid Receptor 2.
Cluster headache pipeline drugs market, by targets
For more target insights, download a free report sample
Mechanisms of Action of Cluster Headache Pipeline Drugs Market
The mechanisms of action of the cluster headache pipeline drugs market are 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 1D Agonist, Calcitonin Gene Related Peptide Inhibitor, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Agonist, Calcium Channel Blocker, and Cannabinoid Receptor 1 Agonist.
Cluster headache pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
Routes of Administration in Cluster Headache Pipeline Drugs Market
The routes of administration in the cluster headache pipeline drugs market are oral, subcutaneous, nasal, intramuscular, intravenous, intraarticular, intradermal, parenteral, topical, and transdermal.
Cluster headache pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in Cluster Headache Pipeline Drugs Market
The molecule types in the cluster headache pipeline drugs market are small molecule and monoclonal antibody.
Cluster headache pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Key Cluster Headache Pipeline Drugs Market Companies
Some of the key companies in the cluster headache pipeline drugs market are Ceruvia Lifesciences LLC, Eli Lilly and Co, Amgen Inc, Amneal Pharmaceuticals Inc, Better Life Pharmaceuticals Inc, Biohaven Pharmaceutical Holding Company Ltd, Bright Minds Biosciences Inc, CCH Pharmaceuticals ApS, Clexio Biosciences Ltd, and Crossject SA.
Cluster headache pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
| Targets | 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 1D, Calcitonin Gene Related Peptide, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide Type 1 Receptor, 5-Hydroxytryptamine Receptor 2C, Calcium Channel, Cannabinoid Receptor 1, and Cannabinoid Receptor 2 |
| Mechanisms of Action | 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 1D Agonist, Calcitonin Gene Related Peptide Inhibitor, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Agonist, Calcium Channel Blocker, and Cannabinoid Receptor 1 Agonist |
| Routes of Administration | Oral, Subcutaneous, Nasal, Intramuscular, Intravenous, Intraarticular, Intradermal, Parenteral, Topical, and Transdermal |
| Molecule Types | Small Molecule and Monoclonal Antibody |
| Key Companies | Ceruvia Lifesciences LLC, Eli Lilly and Co, Amgen Inc, Amneal Pharmaceuticals Inc, Better Life Pharmaceuticals Inc, Biohaven Pharmaceutical Holding Company Ltd, Bright Minds Biosciences Inc, CCH Pharmaceuticals ApS, Clexio Biosciences Ltd, and Crossject SA |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
- Reviews of pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Cluster Headache Syndrome (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Amneal Pharmaceuticals Inc
Better Life Pharmaceuticals Inc
Biohaven Pharmaceutical Holding Company Ltd
Bright Minds Biosciences Inc
CCH Pharmaceuticals ApS
Ceruvia Lifesciences LLC
Clexio Biosciences Ltd
Crossject SA
Eli Lilly and Co
H. Lundbeck AS
Havn Life Sciences Inc
Mind Medicine MindMed Inc
NeuroPharm Inc
Psirenity Inc
Shackelford Pharma Inc
Winston Pharmaceuticals Inc
Xgene Pharmaceutical Inc
Zosano Pharma Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Cluster Headache pipeline drugs market?
The targets of the cluster headache pipeline drugs market are 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 1A, 5-Hydroxytryptamine Receptor 1D, Calcitonin Gene Related Peptide, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide Type 1 Receptor, 5-Hydroxytryptamine Receptor 2C, Calcium Channel, Cannabinoid Receptor 1, and Cannabinoid Receptor 2.
-
What are the mechanisms of action of the Cluster Headache pipeline drugs market?
The mechanisms of action of the cluster headache pipeline drugs market are 5-Hydroxytryptamine Receptor 2A Agonist, 5-Hydroxytryptamine Receptor 1A Agonist, 5-Hydroxytryptamine Receptor 1D Agonist, Calcitonin Gene Related Peptide Inhibitor, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Agonist, Calcium Channel Blocker, and Cannabinoid Receptor 1 Agonist.
-
What are the routes of administration in the Cluster Headache pipeline drugs market?
The routes of administration in the cluster headache pipeline drugs market are oral, subcutaneous, nasal, intramuscular, intravenous, intraarticular, intradermal, parenteral, topical, and transdermal.
-
What are the molecule types in the Cluster Headache pipeline drugs market?
The molecule types in the cluster headache pipeline drugs market are small molecule and monoclonal antibody.
-
Which are the key companies in the Cluster Headache pipeline drugs market?
Some of the key companies in the cluster headache pipeline drugs market are Ceruvia Lifesciences LLC, Eli Lilly and Co, Amgen Inc, Amneal Pharmaceuticals Inc, Better Life Pharmaceuticals Inc, Biohaven Pharmaceutical Holding Company Ltd, Bright Minds Biosciences Inc, CCH Pharmaceuticals ApS, Clexio Biosciences Ltd, and Crossject SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Central Nervous System reports